Currently, Lacerta is focused on gene therapy solutions for Sanfilippo Syndrome Type B, Friedreich’s ataxia, Spinocerebellar ataxia, Pompe disease, and Alzheimer’s.

In November 2020, Lacerta announced a research collaboration and licensing agreement with Belgian drugmaker UCB, that will focus on an unnamed central nervous system disease with a high unmet need.